Cargando…

The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR(+) CD8(+) effector state, and its deletion improves checkpoint blockade

CD8(+) T cell exhaustion (T(EX)) impairs the ability of T cells to clear chronic infection or cancer. While T(EX) are hypofunctional, some T(EX) retain effector gene signatures, a feature associated with killer lectin-like receptor (KLR) expression. Although KLR(+) T(EX) (T(KLR)) may improve control...

Descripción completa

Detalles Bibliográficos
Autores principales: McClory, Susan E., Bardhan, Oishi, Rome, Kelly S., Giles, Josephine R., Baxter, Amy E., Xu, Lanwei, Gimotty, Phyllis A., Faryabi, Robert B., John Wherry, E., Pear, Warren S., Jordan, Martha S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540077/
https://www.ncbi.nlm.nih.gov/pubmed/37527035
http://dx.doi.org/10.1016/j.celrep.2023.112905
Descripción
Sumario:CD8(+) T cell exhaustion (T(EX)) impairs the ability of T cells to clear chronic infection or cancer. While T(EX) are hypofunctional, some T(EX) retain effector gene signatures, a feature associated with killer lectin-like receptor (KLR) expression. Although KLR(+) T(EX) (T(KLR)) may improve control of chronic antigen, the signaling molecules regulating this population are poorly understood. Using single-cell RNA sequencing (scRNA-seq), flow cytometry, RNA velocity, and single-cell T cell receptor sequencing (scTCR-seq), we demonstrate that deleting the pseudokinase Trib1 shifts T(EX) toward CX3CR1(+) intermediates with robust enrichment of T(KLR) via clonal T cell expansion. Adoptive transfer studies demonstrate this shift toward CD8(+) T(KLR) in Trib1-deficient cells is CD8 intrinsic, while CD4-depletion studies demonstrate CD4(+) T cells are required for improved viral control in Trib1 conditional knockout mice. Further, Trib1 loss augments anti-programmed death-ligand 1 (PD-L1) blockade to improve viral clearance. These data identify Trib1 as an important regulator of CD8(+) T(EX) whose targeting enhances the T(KLR) effector state and improves checkpoint inhibitor therapy.